| Literature DB >> 21483780 |
Aaron To1, Yong Bai, Ao Shen, Hao Gong, Sean Umamoto, Sangwei Lu, Fenyong Liu.
Abstract
Human cytomegalovirus (HCMV) is the largest human herpesvirus and its virion contains many viral encoded proteins found in the capsid, tegument, and envelope. In this study, we carried out a yeast two-hybrid (YTH) analysis to study potential binary interactions among 56 HCMV-encoded virion proteins. We have tested more than 3,500 pairwise combinations for binary interactions in the YTH analysis, and identified 79 potential interactions that involve 37 proteins. Forty five of the 79 interactions were also identified in human cells expressing the viral proteins by co-immunoprecipitation (co-IP) experiments. To our knowledge, 58 of the 79 interactions revealed by YTH analysis, including those 24 that were also identified in co-IP experiments, have not been reported before. Novel potential interactions were found between viral capsid proteins and tegument proteins, between tegument proteins, between tegument proteins and envelope proteins, and between envelope proteins. Furthermore, both the YTH and co-IP experiments have identified 9, 7, and 5 interactions that were involved with UL25, UL24, and UL89, respectively, suggesting that these "hub" proteins may function as the organizing centers for connecting multiple virion proteins in the mature virion and for recruiting other virion proteins during virion maturation and assembly. Our study provides a framework to study potential interactions between HCMV proteins and investigate the roles of protein-protein interactions in HCMV virion formation or maturation process.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21483780 PMCID: PMC3069980 DOI: 10.1371/journal.pone.0017796
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1HCMV ORF sequences generated by PCR and cloned in yeast and mammalian expression vectors.
(A) The PCR products for the HCMV ORFs separated on 1% agarose gels. (B) The predicted sizes of the PCR products for the HCMV ORFs based on the PCR primers used.
Figure 2Protein-protein interactions between HCMV ORFs as identified by YTH analysis.
In (A–B), a directional interaction is shown with the interaction existing only in BDUL86-ADUL48.5 (B) but not in BDUL48.5-ADUL86 (A). Interactions detected only in one direction are common in YTH assays and are most likely due to steric hindrance of either bait or prey fusion proteins [21], [22], [23]. In (C–D), an example of reciprocal interactions is shown with BDUL24-ADUL69 and the reverse combination. In (E–F), BDUL-Lam and BDUL-p53 are the human lamin C and murine p53 proteins fused to the BD domain of GAL4, respectively, while ADUL-T is the SV40 large T-antigen fused to the AD domain of GAL4. Murine p53 and SV40 T-antigen interact and serve as a positive control (F) while human lamin C and SV40 T-antigen do not interact and serve as a negative control (E). Diploids were plated on SD/-Leu/-Trp/-Ade/-His/X-α-Gal agar plates to test for protein-protein interactions. Positive interactions had blue yeast colony growth (B, C, D, and F), whereas no interactions were shown by the absence of growth (A and E). We observed similar growth of the diploid yeast cells representing the positive interactions.
Protein-protein interactions of HCMV virion proteins that have either been previously reported or suggested, and were positive in our YTH and co-IP analysis.
| BD ORFs and Function | AD ORFs and Function | Co-IP | Reported in HCMV | Reported in other Herpesviruses | References | ||
|
| |||||||
| UL46 | Minor capsid protein binding protein (E) | UL85 | Minor capsid protein (E) | + | UL46-UL85 | UL38-UL18 (HSV-1) |
|
| UL80 | Protease/Capsid assembly precursor (E) | UL80 | Protease/Capsid assembly precursor (E) | + | UL80.5-UL80.5 | UL26.5-UL26.5 (HSV-1); Orf33-Orf33 (VZV) |
|
| UL85 | Minor capsid protein (E) | UL85 | Minor capsid protein (E) | + | UL85-UL85 |
| |
| UL86 | Major capsid protein (E) | UL48.5 | Smallest capsid protein (E) | + | UL86-UL48/49 |
| |
|
| |||||||
| UL25 | Tegument protein (NE) | UL25 | Tegument protein (NE) | + | UL25-UL25 |
| |
| UL25 | Tegument protein (NE) | UL26 | Transcription (D) | + | UL25-UL26 |
| |
| UL32 | Basic phosphoprotein (E) | UL35 | Tegument (Transcription) (D) | + | UL32-UL35 |
| |
| UL32* | Basic phosphoprotein (E) | UL82 | Transcription (D) | + | UL32-UL82 |
| |
| UL35* | Transcription (D) | UL82 | Transcription (D) | + | UL35-UL82 |
| |
| UL43* | Tegument protein (NE) | UL83 | Tegument (immunomodulation) (NE) | + | UL43-UL83 |
| |
| UL45 | Ribonucleotide reductase homologue (NE) | UL25 | Tegument protein (NE) | + | UL45-UL25 |
| |
| UL45 | Ribonucleotide reductase homologue (NE) | UL69 | Transcription (D) | + | UL45-UL69 | Orf61-Orf57 (KSHV) |
|
| UL47 | Tegument protein (D) | UL48N | Tegument protein (E) | + | UL37-UL36 (PRV), Orf63-Orf64 (KSHV) |
| |
| UL69 | Transcription (D) | UL69 | Transcription (D) | + | UL69-UL69 | Orf57-Orf57 (KSHV) |
|
| UL72 | Unknown function (D) | UL89.2 | DNA packaging/cleavage (E) | + | Orf54-Orf29b (KSHV) |
| |
| UL82 | Transcription (D) | UL82 | Transcription (D) | + | Orf16-Orf16 (VZV) |
| |
| UL82 | Transcription (D) | UL94 | Tegument protein (E) | + | UL82-UL94 |
| |
| UL88 | Unknown function (D) | UL48N | Tegument protein (E) | + | UL88-UL48 |
| |
| UL99 | Envelopment (E) | UL94 | Tegument Protein (E) | + | UL99-UL94 | UL11-UL16 (HSV-1) |
|
| UL112.1 | Early protein (D) | UL112.1 | Early protein (D) | + | UL112-UL112 |
| |
|
| |||||||
| UL77 | DNA packaging/cleavage (E) | UL77 | DNA packaging/cleavage (E) | + | Orf34-Orf34 (VZV) |
| |
Interactions marked by an asterisk represent reciprocal interactions. “+” represents positive interactions identified by co-IP experiments in human cells (co-IP). The ORFs in which deletion results in no viral growth, wildtype-like growth, and significant growth defect in foreskin fibroblasts are marked as “E” (essential), “NE” (non-essential), and “D” (defect) [7].
Figure 3Interaction map of potential interactions between HCMV virion proteins as revealed by YTH analysis.
The shaded hexagon represents the capsid and the shaded sphere represents the viral particle. The nodes (in yellow) within the capsid represent capsid proteins. The circular nodes in blue represent tegument proteins. The rectangular nodes in orange represent viral envelope proteins. The green lines represent interactions identified in one direction only and the red lines represent reciprocal interactions. The solid lines represent the interactions that were positive in both the YTH analysis and co-IP experiments, while the dashed lines represent the putative interactions that were positive only in the YTH analysis. The ORFs in which deletion resulted in no viral growth, wildtype-like growth, and significant growth defect in human foreskin fibroblasts are marked as “E” (essential), “NE” (non-essential), and “D” [7].
Putative protein-protein interactions of HCMV virion proteins that have not been previously reported and were determined by our YTH and co-IP analysis.
| BD ORFs and Function | AD ORFs and Function | Co-IP | ||
|
| ||||
| UL24* | Tegument protein (NE) | UL46 | Minor capsid protein binding protein (E) | + |
| UL24 | Tegument protein (NE) | UL85 | Minor capsid protein (E) | + |
|
| ||||
| UL24 | Tegument protein (NE) | UL24 | Tegument protein (NE) | − (putative) |
| UL24* | Tegument protein (NE) | UL25 | Tegument protein (NE) | + |
| UL24 | Tegument protein (NE) | UL26 | Transcription (D) | − (putative) |
| UL24* | Tegument protein (NE) | UL32 | Basic phosphoprotein (E) | + |
| UL24* | Tegument protein (NE) | UL43 | Tegument protein (NE) | + |
| UL24 | Tegument protein (NE) | UL51 | DNA packaging/cleavage (E) | − (putative) |
| UL24* | Tegument protein (NE) | UL69 | Transcription (D) | + |
| UL24* | Tegument protein (NE) | UL71 | Unknown function (E) | + |
| UL24 | Tegument protein (NE) | UL88 | Unknown function (D) | − (putative) |
| UL24 | Tegument protein (NE) | UL89.2 | DNA packaging/cleavage (E) | + |
| UL24 | Tegument protein (NE) | US22 | Tegument protein (NE) | − (putative) |
| UL24 | Tegument protein (NE) | US23 | Tegument protein (D) | − (putative) |
| UL25* | Tegument protein (NE) | UL43 | Tegument protein (NE) | + |
| UL25 | Tegument protein (NE) | UL89.2 | DNA packaging/cleavage (E) | + |
| UL32 | Basic phosphoprotein (E) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL43 | Tegument protein (NE) | UL89.2 | DNA packaging/cleavage | + |
| UL44 | DNA polymerase accessory protein (E) | UL25 | Tegument protein (NE) | + |
| UL45 | Ribonucleotide reductase homologue (NE) | UL24 | Tegument protein (NE) | − (putative) |
| UL45 | Ribonucleotide reductase homologue (NE) | UL26 | Transcription (D) | + |
| UL45 | Ribonucleotide reductase homologue (NE) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL45 | Ribonucleotide reductase homologue (NE) | US23 | Tegument protein (D) | − (putative) |
| UL54 | DNA polymerase catalytic subunit (E) | UL24 | Tegument protein (NE) | − (putative) |
| UL54 | DNA polymerase catalytic subunit (E) | UL26 | Transcription (D) | − (putative) |
| UL54 | DNA polymerase catalytic subunit (E) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL69 | Transcription (D) | UL25 | Tegument protein (NE) | − (putative) |
| UL69 | Transcription (D) | UL48N | Tegument protein (E) | + |
| UL69 | Transcription (D) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL71 | Unknown function (E) | UL26 | Transcription (D) | − (putative) |
| UL71 | Unknown function (E) | UL51 | DNA packaging/cleavage (E) | + |
| UL71 | Unknown function (E) | UL71 | Unknown function (E) | − (putative) |
| UL71 | Unknown function (E) | UL89.2 | DNA packaging/cleavage (E) | + |
| UL72 | Unknown function (D) | UL24 | Tegument protein (NE) | + |
| UL72 | Unknown function (D) | UL26 | Transcription (D) | − (putative) |
| UL72 | Unknown function (D) | UL94 | Tegument Protein (E) | − (putative) |
| UL83 | Tegument (immunomodulation) (NE) | UL25 | Tegument protein (NE) | + |
| UL89.2 | DNA packaging/cleavage (E) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL103 | Unknown function (D) | UL48N | Tegument protein (E) | − (putative) |
| UL103 | Unknown function (D) | UL103 | Unknown function (D) | − (putative) |
| UL112.1 | Early protein (D) | UL25 | Tegument protein (NE) | − (putative) |
| UL122 | IE-2 (Transcription) (E) | UL25 | Tegument protein (NE) | + |
| UL122 | IE-2 (Transcription) (E) | UL122 | IE-2 (Transcription) (E) | + |
| US24 | Tegument protein (NE) | US23 | Tegument protein (D) | − (putative) |
|
| ||||
| UL24* | Tegument protein (NE) | UL77 | DNA packaging/cleavage (E) | + |
| UL32 | (Tegument) Basic phosphoprotein (E) | UL77 | DNA packaging/cleavage (E) | − (putative) |
| UL38 | Apoptosis Inhibitor (D) | UL24 | Tegument protein (NE) | − (putative) |
| UL38 | Apoptosis Inhibitor (D) | UL89.2 | DNA packaging/cleavage (E) | − (putative) |
| UL43 | Tegument protein (NE) | UL77 | DNA packaging/cleavage (E) | − (putative) |
| UL45 | Ribonucleotide reductase homologue (NE) | UL77 | DNA packaging/cleavage (E) | − (putative) |
| UL50 | Nuclear egress (E) | UL48N | Tegument protein (E) | − (putative) |
| UL50 | Nuclear egress (E) | UL48C | Tegument protein (E) | − (putative) |
| UL54 | DNA polymerase catalytic subunit (E) | UL77 | DNA packaging/cleavage (E) | − (putative) |
| UL69 | Transcription (D) | UL77 | DNA packaging/cleavage (E) | − (putative) |
| UL103 | Unknown function (D) | UL22A | Glycoprotein (D) | − (putative) |
| UL132 | Glycoprotein (D) | UL48N | Tegument protein (E) | + |
|
| ||||
| UL50 | Nuclear egress (E) | UL77 | DNA packaging/cleavage (E) | + |
| UL132 | Glycoprotein (D) | UL22A | Glycoprotein (D) | + |
Interactions marked by an asterisk represent reciprocal interactions. “+” and “−” represent positive or negative interactions identified by co-IP experiments in human cells (co-IP). The ORFs in which deletion results in no viral growth, wildtype-like growth, and significant growth defect in foreskin fibroblasts are marked as “E” (essential), “NE” (non-essential), and “D” (defect) [7].
Figure 4Co-immunoprecipitation (co-IP) of transiently expressed viral proteins.
HeLa cells were co-transfected with a combination of two plasmids expressing HA- and myc-tagged proteins. Panels (A) and (B) are inputs that show the expression of HA- and myc-tagged proteins detected by Western blot analysis with anti-HA and anti-myc antibodies, respectively. Lanes 1 and 9 are from the same cell lysate, likewise, lanes 2 and 10, and so on. Lanes 7, 8, 15, and 16 are negative controls based on our YTH data that revealed no interactions. Panels (C) and (D) represent co-IP experiments (IP-anti-HA) with anti-HA agarose antibodies and visualized by Western blot analysis using anti-HA and anti-myc antibodies, respectively. Panels (E) and (F) are co-IP experiments (IP-anti-myc) with anti-myc agarose antibodies (IP-anti-Myc) and visualized by Western blot analysis using anti-HA and anti-myc antibodies, respectively. The protein species, which migrated at approximately 82 kDa and was detected by the anti-HA antibody in the input protein samples of the cell lysate (A) but not in the protein samples immunoprecipitated with either the anti-HA or anti-myc antibodies (C and E), may represent a cellular protein that non-specifically reacts with the anti-HA antibody.